A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
NCT ID: NCT03735511
Last Updated: 2020-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
270 participants
OBSERVATIONAL
2018-11-20
2020-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province
NCT03478943
The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province
NCT03333967
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
NCT03219593
Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer
NCT03255811
Apatinib for the Elderly Advanced Gastric Cancer
NCT03104283
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients received apatinib treatment at least once.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LinkDoc Technology (Beijing) Co. Ltd.
INDUSTRY
Henan Cancer Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henan Cancer Hospital
Zhengzhou, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APA-GC-2018-HNZL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.